SG11202001441WA - Polymorphic form of tg02 - Google Patents
Polymorphic form of tg02Info
- Publication number
- SG11202001441WA SG11202001441WA SG11202001441WA SG11202001441WA SG11202001441WA SG 11202001441W A SG11202001441W A SG 11202001441WA SG 11202001441W A SG11202001441W A SG 11202001441WA SG 11202001441W A SG11202001441W A SG 11202001441WA SG 11202001441W A SG11202001441W A SG 11202001441WA
- Authority
- SG
- Singapore
- Prior art keywords
- polymorphic form
- polymorphic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762547157P | 2017-08-18 | 2017-08-18 | |
| PCT/US2018/000264 WO2019035985A1 (en) | 2017-08-18 | 2018-08-17 | POLYMORPHIC FORM OF TG02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202001441WA true SG11202001441WA (en) | 2020-03-30 |
Family
ID=65359869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202001441WA SG11202001441WA (en) | 2017-08-18 | 2018-08-17 | Polymorphic form of tg02 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10544162B2 (ko) |
| EP (2) | EP3668876B1 (ko) |
| JP (1) | JP7250764B2 (ko) |
| KR (1) | KR20200078481A (ko) |
| CN (1) | CN111372934B (ko) |
| AU (1) | AU2018317865B2 (ko) |
| CA (1) | CA3073270A1 (ko) |
| IL (1) | IL272697B2 (ko) |
| MX (1) | MX2020001875A (ko) |
| RU (1) | RU2020111019A (ko) |
| SG (1) | SG11202001441WA (ko) |
| TW (1) | TWI785098B (ko) |
| WO (1) | WO2019035985A1 (ko) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3018875A1 (en) | 2016-03-24 | 2017-09-28 | Tragara Pharmaceuticals, Inc. | Treatment of cancer with tg02 |
| WO2020219603A1 (en) | 2019-04-22 | 2020-10-29 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Use of tg02 for treating gliomas in pediatric subjects |
| CN110664760B (zh) * | 2019-10-28 | 2020-10-23 | 浙江大学 | 一种负载vegfr靶向抑制剂的药物载体及其制备方法和应用 |
| WO2024031406A1 (en) * | 2022-08-10 | 2024-02-15 | Xiang Li | Idh mutations as biomarkers for zotiraciclib therapy |
| CN115429793A (zh) * | 2022-08-15 | 2022-12-06 | 复旦大学附属中山医院 | 一种化合物在制备治疗肝细胞癌药物中的应用 |
| CN115305251B (zh) * | 2022-08-30 | 2023-06-27 | 中国农业科学院北京畜牧兽医研究所 | Ap2-mybl2分子模块在调控原花色素生物合成中的应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1982001011A1 (en) | 1980-09-24 | 1982-04-01 | Corp Cetus | Diagnostic method and probe |
| DE3381518D1 (de) | 1982-01-22 | 1990-06-07 | Cetus Corp | Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel. |
| US4582788A (en) | 1982-01-22 | 1986-04-15 | Cetus Corporation | HLA typing method and cDNA probes used therein |
| US4683194A (en) | 1984-05-29 | 1987-07-28 | Cetus Corporation | Method for detection of polymorphic restriction sites and nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| CA1284931C (en) | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| CA1338457C (en) | 1986-08-22 | 1996-07-16 | Henry A. Erlich | Purified thermostable enzyme |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US6605712B1 (en) | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
| AU6703198A (en) | 1997-03-21 | 1998-10-20 | Brigham And Women's Hospital | Immunotherapeutic ctla-4 binding peptides |
| JP4896327B2 (ja) | 1999-08-23 | 2012-03-14 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | Ｐｄ−１、ｂ７−４の受容体、およびその使用 |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| ATE481985T1 (de) | 2002-07-03 | 2010-10-15 | Ono Pharmaceutical Co | Immunpotenzierende zusammensetzungen |
| KR101914254B1 (ko) | 2005-02-18 | 2018-11-02 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 조합 및 투여 방식, 및 조합 요법 |
| EP1896582A4 (en) | 2005-05-09 | 2009-04-08 | Ono Pharmaceutical Co | HUMAN MONOCLONAL ANTIBODIES FOR PROGRAMMED DEATH 1 (MP-1) AND METHODS FOR TREATING CANCER USING ANTI-MP-1 ANTIBODIES ALONE OR ASSOCIATED WITH OTHER IMMUNOTHERAPIES |
| AU2006316072B2 (en) * | 2005-11-16 | 2011-12-22 | S*Bio Pte Ltd | Heteroalkyl linked pyrimidine derivatives |
| PL2170959T3 (pl) | 2007-06-18 | 2014-03-31 | Merck Sharp & Dohme | Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| PL2350129T3 (pl) | 2008-08-25 | 2015-12-31 | Amplimmune Inc | Kompozycje antagonistów PD-1 i sposoby stosowania |
| HRP20240240T1 (hr) | 2008-12-09 | 2024-04-26 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
| US20120148661A1 (en) | 2009-04-15 | 2012-06-14 | Poniard Pharmaceuticals, Inc. | High bioavailability oral picoplatin anti-cancer therapy |
| JP4965623B2 (ja) | 2009-09-30 | 2012-07-04 | インターナショナル・ビジネス・マシーンズ・コーポレーション | 所定のソフトウェアの実行パラメータを入力フィールドへ入力することを支援するための方法、システム、およびプログラム |
| WO2011097525A1 (en) | 2010-02-05 | 2011-08-11 | Tragara Pharmaceuticals, Inc. | Solid state forms of macrocyclic kinase inhibitors |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| WO2013043569A1 (en) | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| BR122022015975B1 (pt) | 2012-05-15 | 2024-01-02 | Bristol-Myers Squibb Company | Anticorpos monoclonais, kit para o tratamento de um indivíduo afligido com um câncer, processo para medir pd-l1 membranoso em células tumorais isoladas e uso do anticorpo ou uma porção que se liga ao antígeno do mesmo |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| JP2015525781A (ja) | 2012-07-31 | 2015-09-07 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | 免疫応答の調節 |
| EP3712177A1 (en) | 2013-03-15 | 2020-09-23 | GlaxoSmithKline Intellectual Property Development Limited | Anti-lag-3 binding proteins |
| EP3043816B1 (en) | 2013-09-11 | 2019-08-14 | MedImmune Limited | Anti-b7-h1 antibodies for treating tumors |
| US20150252434A1 (en) | 2014-03-07 | 2015-09-10 | University Health Network | Methods and compositions for detection of targets involved in cancer metastasis |
| ES2770684T3 (es) | 2014-03-14 | 2020-07-02 | Novartis Ag | Moléculas de anticuerpos contra LAG-3 y usos de los mismos |
| CA3018875A1 (en) | 2016-03-24 | 2017-09-28 | Tragara Pharmaceuticals, Inc. | Treatment of cancer with tg02 |
-
2018
- 2018-08-17 AU AU2018317865A patent/AU2018317865B2/en active Active
- 2018-08-17 WO PCT/US2018/000264 patent/WO2019035985A1/en unknown
- 2018-08-17 RU RU2020111019A patent/RU2020111019A/ru unknown
- 2018-08-17 MX MX2020001875A patent/MX2020001875A/es unknown
- 2018-08-17 IL IL272697A patent/IL272697B2/en unknown
- 2018-08-17 KR KR1020207007701A patent/KR20200078481A/ko not_active Application Discontinuation
- 2018-08-17 EP EP18846214.7A patent/EP3668876B1/en active Active
- 2018-08-17 EP EP24152903.1A patent/EP4364741A2/en active Pending
- 2018-08-17 JP JP2020508985A patent/JP7250764B2/ja active Active
- 2018-08-17 CA CA3073270A patent/CA3073270A1/en active Pending
- 2018-08-17 CN CN201880065266.0A patent/CN111372934B/zh active Active
- 2018-08-17 TW TW107128900A patent/TWI785098B/zh active
- 2018-08-17 US US15/998,872 patent/US10544162B2/en active Active
- 2018-08-17 SG SG11202001441WA patent/SG11202001441WA/en unknown
-
2020
- 2020-01-24 US US16/751,969 patent/US20200262843A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20190055263A1 (en) | 2019-02-21 |
| IL272697B2 (en) | 2023-12-01 |
| US20200262843A1 (en) | 2020-08-20 |
| CN111372934A (zh) | 2020-07-03 |
| WO2019035985A1 (en) | 2019-02-21 |
| CA3073270A1 (en) | 2019-02-21 |
| TW201920199A (zh) | 2019-06-01 |
| RU2020111019A3 (ko) | 2022-03-18 |
| EP3668876A1 (en) | 2020-06-24 |
| EP4364741A2 (en) | 2024-05-08 |
| US10544162B2 (en) | 2020-01-28 |
| RU2020111019A (ru) | 2021-09-20 |
| TWI785098B (zh) | 2022-12-01 |
| MX2020001875A (es) | 2020-07-29 |
| IL272697A (en) | 2020-04-30 |
| EP3668876B1 (en) | 2024-01-24 |
| AU2018317865A1 (en) | 2020-03-19 |
| CN111372934B (zh) | 2024-04-26 |
| EP3668876A4 (en) | 2021-04-28 |
| IL272697B1 (en) | 2023-08-01 |
| JP7250764B2 (ja) | 2023-04-03 |
| AU2018317865B2 (en) | 2023-03-16 |
| JP2020531463A (ja) | 2020-11-05 |
| KR20200078481A (ko) | 2020-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272888B1 (en) | Uses of piperidinyl-indole derivatives | |
| IL268915A (en) | Polymorphic compounds and their uses | |
| HK1252845A1 (zh) | 勞拉替尼游離碱的結晶形式 | |
| IL263050B (en) | History of Subtirum | |
| IL269409A (en) | Combinations of chk1- and wee1 - inhibitors | |
| IL272697A (en) | A polymorphic form of TG02 | |
| IL292245A (en) | Polymorphic forms of rad1901–2hcl | |
| IL274627A (en) | Solid state form of valbenazine | |
| EP3894768C0 (en) | METHOD FOR CRYOHARDENING | |
| PL3532457T3 (pl) | Postacie krystaliczne hydroksynorketaminy | |
| ZA202003487B (en) | Polymorphs | |
| GB2553390B (en) | Method of manufacture | |
| GB201407807D0 (en) | Polymorphic form | |
| IL270961A (en) | Crystalline form of N-butyldeoxygalactonogirimycin | |
| GB201407820D0 (en) | Polymorphic form | |
| IL263363A (en) | Polymorph of nintedanib | |
| GB201407813D0 (en) | Polymorphic form | |
| GB201703041D0 (en) | Installation of mono-pile | |
| GB201704816D0 (en) | Method of manufacture | |
| GB201721386D0 (en) | Chrondogy of time-wave | |
| IL270937A (en) | Crystalline forms of saltalicib | |
| GB2567222B (en) | Method of manufacture | |
| PL3629754T3 (pl) | Sposób przygotowania rosiczki | |
| GB201717104D0 (en) | Polymorphs | |
| GB201707716D0 (en) | Point of interest location specification |